$ORKA
Oruka Therapeutics, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019027966 Filed on August 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.070M $1.120M $900.0K
YoY Change 7.0% 6.67% -38.36%
% of Gross Profit
Research & Development $440.0K $660.0K $630.0K
YoY Change -61.74% -61.63% -77.74%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $1.510M $1.781M $1.530M
YoY Change -29.96% -35.77% -64.42%
Operating Profit -$1.508M -$1.781M
YoY Change -35.77%
Interest Expense $3.000K $3.000K $40.00K
YoY Change -92.5% 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.463M -$1.746M -$1.490M
YoY Change -30.86% -36.16% -65.02%
Income Tax -$27.00K -$82.00K $0.00
% Of Pretax Income
Net Earnings -$1.436M -$1.664M -$1.489M
YoY Change -32.14% -39.16% -64.52%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.143M -$1.844M -$1.935M
COMMON SHARES
Basic Shares Outstanding 1.099M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.00M $8.000M $6.600M
YoY Change 4.17% -33.88% -43.84%
Cash & Equivalents $9.966M $8.006M $6.608M
Short-Term Investments $0.00
Other Short-Term Assets $357.0K $500.0K $169.0K
YoY Change -10.75% -16.67% -69.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.32M $8.500M $6.777M
YoY Change 3.23% -33.07% -44.9%
LONG-TERM ASSETS
Property, Plant & Equipment $13.00K $100.0K $24.00K
YoY Change -42.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $24.00K $0.00 $24.00K
YoY Change 0.0%
Total Long-Term Assets $65.00K $100.0K $48.00K
YoY Change -35.0% 0.0% -27.27%
TOTAL ASSETS
Total Short-Term Assets $10.32M $8.500M $6.777M
Total Long-Term Assets $65.00K $100.0K $48.00K
Total Assets $10.39M $8.600M $6.825M
YoY Change 2.85% -32.81% -44.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $254.0K $300.0K $230.0K
YoY Change -36.5% -62.5% -63.02%
Accrued Expenses $900.0K $1.000M $600.0K
YoY Change 28.57% 11.11% -57.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.199M $1.300M $793.0K
YoY Change 9.0% -23.53% -61.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.199M $1.300M $793.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.200M $1.300M $800.0K
YoY Change 9.09% -23.53% -61.9%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $145.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.189M $7.318M $6.032M
YoY Change
Total Liabilities & Shareholders Equity $10.40M $8.600M $6.800M
YoY Change 2.97% -32.81% -45.01%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$1.436M -$1.664M -$1.489M
YoY Change -32.14% -39.16% -64.52%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$1.190M -$1.566M -$1.340M
YoY Change -47.35% -49.01% -68.02%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.150M 2.964M -110.0K
YoY Change -1600.0% -13.33% -1200.0%
NET CHANGE
Cash From Operating Activities -1.190M -1.566M -1.340M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 3.150M 2.964M -110.0K
Net Change In Cash 1.960M 1.398M -1.450M
YoY Change -179.35% -6454.55% -354.39%
FREE CASH FLOW
Cash From Operating Activities -$1.190M -$1.566M -$1.340M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$1.190M -$1.566M -$1.340M
YoY Change -47.35% -49.02% -68.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10275000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
150000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
831000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
793000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
413000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24000
CY2019Q2 us-gaap Assets
Assets
10388000
CY2018Q4 us-gaap Assets
Assets
6825000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
254000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
230000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
114000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9966000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6608000
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
357000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
169000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
10323000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6777000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1199000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
144965000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1455556
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1455556
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1068000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2055000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
2156000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1508000
CY2019Q2 us-gaap Interest Expense
InterestExpense
3000
us-gaap Interest Expense
InterestExpense
6000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1463000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2116000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3209000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4851000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-27000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1436000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2116000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3100000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3415000
CY2018Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2735000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
11054000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
8998000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1593000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
7463000
CY2018Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2018Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-1489000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2900000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8702000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9635000
us-gaap Interest Paid Net
InterestPaidNet
3000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1664000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
7318000
abio Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
32000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-13000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-36000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
94000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2756000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
3050000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3049000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6517000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3532000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
287000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
117000
us-gaap Repayments Of Short Term Debt Maturing In More Than Three Months
RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths
116000
us-gaap Repayments Of Short Term Debt Maturing In More Than Three Months
RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths
206000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6114000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3209000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3358000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
933000
us-gaap Interest Paid Net
InterestPaidNet
6000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
109000
abio Vendor Finance Agreement
VendorFinanceAgreement
233000
abio Vendor Finance Agreement
VendorFinanceAgreement
105000
abio Common Stock Offering Costs Accrued Reversal But Not Yet Paid
CommonStockOfferingCostsAccruedReversalButNotYetPaid
68000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
60000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p>
us-gaap Revenues
Revenues
0
CY2019Q2 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
168695
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
183033
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2016Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P38M
CY2016Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
36-month
us-gaap Lessee Operating Lease Assumptions And Judgments Allocation Of Lease And Nonlease Component
LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent
The lease includes real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
38000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
38000
abio Royalty Buy Down Due Period
RoyaltyBuyDownDuePeriod
P6M
CY2019Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
135862
CY2019Q2 abio Weighted Average Exercise Price Of Warrants Or Rights
WeightedAverageExercisePriceOfWarrantsOrRights
113.04

Files In Submission

Name View Source Status
0001564590-19-027966-index-headers.html Edgar Link pending
0001564590-19-027966-index.html Edgar Link pending
0001564590-19-027966.txt Edgar Link pending
0001564590-19-027966-xbrl.zip Edgar Link pending
abio-10q_20190630.htm Edgar Link pending
abio-20190630.xml Edgar Link completed
abio-20190630.xsd Edgar Link pending
abio-20190630_cal.xml Edgar Link unprocessable
abio-20190630_def.xml Edgar Link unprocessable
abio-20190630_lab.xml Edgar Link unprocessable
abio-20190630_pre.xml Edgar Link unprocessable
abio-ex311_7.htm Edgar Link pending
abio-ex312_8.htm Edgar Link pending
abio-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending